Edgewise Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Edgewise Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-11.0%
Buyback Yield
| Total Shareholder Yield | -11.0% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation
Nov 26
Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)
Sep 19We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Aug 12Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal
Aug 05Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run
May 10We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate
May 10Edgewise Therapeutics: Behind The Massive Rally
Feb 18Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Dec 07Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans
Aug 16Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Apr 28We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Jan 13Edgewise Therapeutics proposes $100M stock offering plan
Sep 13Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02
Aug 04Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Aug 02We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Mar 24We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Nov 23Edgewise Therapeutics names new chief medical officer
Apr 27Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if EWTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EWTX's dividend payments have been increasing.
Dividend Yield vs Market
| Edgewise Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (EWTX) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Pharmaceuticals) | 2.5% |
| Analyst forecast (EWTX) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate EWTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EWTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate EWTX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EWTX has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 15:05 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Edgewise Therapeutics, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cory Kasimov | Evercore ISI |
| Madhu Kumar | Goldman Sachs |
| Paul Choi | Goldman Sachs |